Health Research Methods, Evidence, and Impact

Mitchell A.H. Levine

BSc (McGill), MSc (McMaster), MD (Calgary), FRCPC, FISPE, FACP

Professor, Department of Health Research Methods, Evidence, and Impact

Joint Member, Department of Medicine, Division of Clinical Pharmacology

Director, Centre for Evaluation of Medicines

Active Staff, St. Joseph's Hospital

Editor-in-Chief, Journal of Population Therapeutics and Clinical Pharmacology,  Canadian Journal of General Internal Medicine 

Associate Editor, ACP Journal Club: Evidence Based Medicine

Consultant, Ontario Drug Benefit Program

Member, Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology, Health Canada

Vice-Chair, Patented Medicine Prices Review Board

905.523.7284 x 2223

Centre for Evaluation of Medicines
25 Main St. West, Suite 2000, 20th floor
Hamilton, ON L8P 1H1

Administrative Assistant: Sheri Burns
905.523.7284 x 2225

Academic Interests

Dr. Levine's principal research interests are in assessing prescription drug use in the community and developing methods for promoting cost-effective use of drug therapy. This has been done through the Prescription Medication Monitoring Programme, which collects data on how drugs are actually used in the community and the impact that they have on health care resource use and on patient quality of life. A second focus is the dissemination of evidence-based prescribing information for primary care physicians through the "Drugs of Choice" formulary. A third area of research interest involves studying of how physician and patient values influence the use of drug therapies.

Current HRM Graduate Students
Benjamin Lo, PhD
Laveen Kamboj, PhD

Recent HRM Graduate Students
Joanne Duncan, MSc (2011)

Selected Publications

  1. Rodger IW, Dilar D, Dwyer J, et al.  Evidence against the Involvement of Chronic Cerebrospinal Venous Abnormalities in Multiple Sclerosis. A Case-Control Study. PLoS ONE 2013 8(8): e72495. doi:10.1371/journal.pone.0072495
  2. Hyewon HL, Levine M. Determining the threshold of acceptability of an ICER when natural health units are used. Journal of Population Therapeutics and Clinical Pharmacology 2012;19(2):e234-8.
  3. Levine MA, El-Nahas AI, Asa B Relative risk and odds ratio data are still portrayed with inappropriate scales in the medical literature. J Clin Epidemiol. 2010 Sep;63(9):1045-7. Epub 2010 May 1.
  4. Levine MAH, Xu S, Gaebel K, Brazier N, Bedard M, Brazil K, Lohfeld L, MacLeod S. Self-Reported Use of Natural Health Products: A Cross-Sectional Telephone Survey in Older Ontarians. Am J Geriatr Pharmacother. 2009;7:383-392.
  5. Farahani P, Levine M, Gaebel K, LeLorier J, Perreault S, Gillis J, Soon J.  Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care.  Clin Invest Med 2007;30(2)E63-E69.
  6. Singh SR, Levine MAH.  Potential Interactions between Pharmaceuticals and Natural Health Products in Canada:   J Clin Pharmacol 2007;47:1-10
  7. Farahani P, Goeree R, Levine M.  A comparison between integrating clinical practice setting and randomised controlled trial setting into economic evaluation models of therapeutics. Journal of Evaluation in Clinical Practice 2006;12:463-470.
  8. Farahani P, Levine M, Gaebel K, Wang E, Khalidi N.  Community-Based Evaluation of Etanercept in Rheumatoid Arthritis Patients.  J Rheumatol 2006;33:665-70.
  9. Levine MAH, Gaebel K. A study of patient responses to a perceived change in salbutamol metered dose inhalers. J Generic Med 2005;2(3):201-208.
  10. McCormack JP, Dolovich L, Levine M et al. Providing evidence-based information to patients in general practice and pharmacies: What is the acceptability, usefulness and impact on drug use? Health Expectations 2003;6:281-9.


Search for citations for Dr. Levine on PubMed